Breast cancer, menopause, and long-term survivorship: critical issues for the 21st century Patricia A. Ganz, MD The American Journal of Medicine Volume 118, Issue 12, Pages 136-141 (December 2005) DOI: 10.1016/j.amjmed.2005.09.047 Copyright © 2005 Elsevier Inc. Terms and Conditions
Figure 1 Percentage of breast cancer survivors (n = 1, 098) reporting hot flashes, night sweats, and vaginal discharge according to type of adjuvant therapy (Rx), assessed about 3 years after diagnosis. All statistical comparisons were adjusted for age and time since diagnosis, and all tests were done using likelihood ratio χ2 tests based on logistic regressions with and without treatment indicators. Frequencies presented are unadjusted for age and time since diagnosis. *For all values, P <0.0001. Chem = chemotherapy; Tam = tamoxifen. (Adapted from Recent Results Cancer Res.29) The American Journal of Medicine 2005 118, 136-141DOI: (10.1016/j.amjmed.2005.09.047) Copyright © 2005 Elsevier Inc. Terms and Conditions
Figure 2 Percentage of breast cancer survivors (n = 1, 098) reporting vaginal dryness, dyspareunia, and weight gain according to type of adjuvant therapy (Rx), assessed about 3 years after diagnosis. All statistical comparisons were adjusted for age and time since diagnosis, and all tests were done using likelihood ratio χ2 tests based on logistic regressions with and without treatment indicators. Frequencies presented are unadjusted for age and time since diagnosis. *For all values, P <0.01. Chem = chemotherapy; Tam = tamoxifen. (Adapted from Recent Results Cancer Res.29) The American Journal of Medicine 2005 118, 136-141DOI: (10.1016/j.amjmed.2005.09.047) Copyright © 2005 Elsevier Inc. Terms and Conditions